LLY directional thesis
Cheaper GLP-1s and a new oral pill turn falling prices into a flood of new prescriptions, and the maker holding over 60% of the US obesity market rides that volume even as headline prices drop.
“But it's also worse for the system because now we've spent all this money for medications and then had rebound weight gain or falling off medication or so on.”71:33claim_id
mcl_79fd9f3abd1d8825d3open evidence ↗Human-reviewed public claim.
Evidence URL, source timestamp, and excerpt are attached to this permanent claim page.
Creators or reviewers can request reclassification, context, or entity corrections without erasing the source record.